Brain and memory supplements: fifteen products, five pathways

Bacopa monnieri, for memory specifically. Multiple randomised trials have found modest improvements in delayed word recall, and the effect sizes are small but they replicate, which is more than most of this category manages. The catch is time: bacopa trials run eight to twelve weeks before separating from placebo, so a four-week trial of it tells you nothing. Its common side effect is digestive upset, reduced by taking it with food.

Mechanistically it is a drug. Huperzine A inhibits acetylcholinesterase, the same enzyme target as prescription donepezil and rivastigmine, and it is regulated as a medicine in some countries while being sold as a supplement in the United States. That has two consequences worth knowing. Taken alongside a prescribed cholinesterase inhibitor the effects stack, which is an interaction rather than a bonus. And continuous daily use is not how it was studied, which is why cycling is commonly advised.

The large trials say no. The Ginkgo Evaluation of Memory study followed several thousand older adults for around six years and found no reduction in dementia incidence against placebo. Ginkgo does have real effects on peripheral and cerebral circulation, and smaller studies suggest modest benefits for some cognitive measures, but the prevention claim specifically has been tested at scale and did not hold up. Ginkgo also has genuine antiplatelet activity, so it matters if you take warfarin, clopidogrel or aspirin.

Several, and they are worth excluding before spending anything. Vitamin B12 deficiency, underactive thyroid, obstructive sleep apnoea, depression, and the anticholinergic burden of ordinary medications including some antihistamines, bladder drugs and tricyclics. Each of those can produce genuine cognitive fog, each is detectable with a straightforward test or medication review, and each improves when treated. A supplement aimed at a thyroid problem is money spent in the wrong place.

Yes, meaningfully. Citicoline, also sold as CDP-choline, crosses into the brain and supplies both choline for acetylcholine synthesis and cytidine for membrane phospholipids. Plain choline bitartrate in a multivitamin is a cheaper precursor with weaker central delivery. Alpha-GPC is the third form and behaves similarly to citicoline. If a label lists choline without specifying the form, it is almost certainly the cheap one.

More than in most, because the active doses here are narrow. Bacopa needs roughly 300 mg of a standardised extract, citicoline is studied around 250 to 500 mg, and Huperzine A is active in the microgram range where overshooting matters. A blend that lists eleven botanicals under a single 800 mg total cannot be delivering research doses of more than two or three of them. The long list is the marketing; the undisclosed split is the problem.